- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004360
Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus
OBJECTIVES:
I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PROTOCOL OUTLINE: A detailed family history is obtained from all participants. Whenever possible, standard growth curves of affected children are obtained.
Participants then undergo clinical studies of antidiuretic function. A standard fluid deprivation-vasopressin challenge is performed with timed measurements of osmolality, electrolytes, creatinine, and vasopressin. The next day, blood pressure, plasma cyclic AMP, GMP, von Willebrand Factor, Factor VIII, and urine osmolality are measured during a water load desamino-D-arginine vasopressin (dDAVP) infusion test.
Participants with a confirmed diagnosis of congenital diabetes insipidus are then treated with chlorothiazide. Daily urine volume and osmolality are determined before and after therapy. Sodium and fluid are not restricted.
For each family, the entire vasopressin V2 gene of at least 1 affected male, and where possible at least 1 obligate carrier and 1 unaffected brother of a patient is sequenced. In addition, a detailed Xq28 haplotype analysis is done to identify the origin of de novo mutations. If no mutation is found and the disorder is not transmitted in an X-linked mode, both alleles of the gene that codes for aquaporin-II are also sequenced. DNA is collected by mail from as many kindred as possible who do not participate in the clinical studies.
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
- Known or suspected congenital nephrogenic diabetes insipidus
- Clinically and genetically unaffected relatives entered as controls
--Patient Characteristics--
- Age: 6 months to 70 years
Study Plan
How is the study designed?
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Gary L. Robertson, Northwestern University
Publications and helpful links
General Publications
- Bichet DG, Birnbaumer M, Lonergan M, Arthus MF, Rosenthal W, Goodyer P, Nivet H, Benoit S, Giampietro P, Simonetti S, et al. Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am J Hum Genet. 1994 Aug;55(2):278-86.
- Sadeghi H, Robertson GL, Bichet DG, Innamorati G, Birnbaumer M. Biochemical basis of partial nephrogenic diabetes insipidus phenotypes. Mol Endocrinol. 1997 Nov;11(12):1806-13. doi: 10.1210/mend.11.12.0017.
- Robertson GL, McLeod JF, Zerbe RL, et al.: Vasopressin function in heritable forms of diabetes insipidus. In: Gross P, Richter D, Robertson GL, eds.: Vasopressin: IV International Vasopressin Conference, May 23-27, 1993, Berlin Germany. Paris: John Libbey Eurotext, 1993, pp 493-503.
- Wenkert D, Merendino JJ Jr, Shenker A, Thambi N, Robertson GL, Moses AM, Spiegel AM. Novel mutations in the V2 vasopressin receptor gene of patients with X-linked nephrogenic diabetes insipidus. Hum Mol Genet. 1994 Aug;3(8):1429-30. doi: 10.1093/hmg/3.8.1429. No abstract available.
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Pituitary Diseases
- Diabetes Insipidus
- Diabetes Insipidus, Nephrogenic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Sodium Chloride Symporter Inhibitors
- Chlorothiazide
Other Study ID Numbers
- 199/11929
- NU-513
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Insipidus, Nephrogenic
-
Lady Davis InstituteCompletedLithium Use, Nephrogenic Diabetes InsipidusCanada
-
Emory UniversityTerminated
-
Universitair Ziekenhuis BrusselCompletedNephrogenic Diabetes InsipidusBelgium
-
Mayo ClinicHopital du Sacre-Coeur de MontrealRecruitingAutosomal Dominant Polycystic Kidney Disease | Nephrogenic Diabetes Insipidus | Acquired Nephrogenic Diabetes Insipidus | Congenital Nephrogenic Diabetes InsipidusUnited States
-
University of Colorado, DenverUniversity of AarhusCompletedNephrogenic Diabetes InsipidusUnited States, Denmark
-
Radboud University Medical CenterNot yet recruitingBipolar Disorder | Concentration Ability Impaired | Nephrogenic Diabetes Insipidus | Lithium Toxicities | Lithium - Induced NephropathyNetherlands
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Ferring PharmaceuticalsCompletedCentral Diabetes InsipidusJapan
-
University Hospital, Basel, SwitzerlandRecruitingCentral Diabetes Insipidus (cDI)Switzerland
-
Elizabeth Austen LawsonNot yet recruitingCentral Diabetes InsipidusUnited States
Clinical Trials on chlorothiazide
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Vascular Diseases | Hypertension
-
University of VirginiaTerminatedCardiovascular Diseases | Heart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure AcuteUnited States
-
Ochsner Health SystemWithdrawnAcute Decompensated Heart FailureUnited States
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart FailureUnited States
-
Vanderbilt UniversityCompletedHeart FailureUnited States
-
National University of Ireland, Galway, IrelandSuspended
-
University of UtahBoston University; University of Pennsylvania; Northwestern University; Columbia... and other collaboratorsCompleted